This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
As CLL patients and caregivers, we sometimes feel that we are adrift in a universe of unfamiliar terminology. Well, mark your calendars for our June 29th webinar, Learning to Decode Your Blood Test Results for CLL with Dr. Susan Leclair and become conversant in the lingo! As the COVID-19 vaccine has fallen short of good protection for many CLL patients, we continue to help you stay connected with the latest research on this topic and keep you grounded in the stories of how those in similar circumstances are coping. This week’s Alert also looks at research for combining zanubrutinib with venetoclax in treatment-naïve patients. And finally, if you are going out, a mask should be your number one take-along! You look great in it; you really do!
Learning to Decode Your Blood Test Results for CLL will be held on Tuesday, June 29th at 10:00 AM PT, 11:00 AM MT, 12:00 PM CT and 1:00 PM ET. Do you ever look at your blood test results from the lab and feel like you are reading Latin? Or you see a result that is outside of the normal range and aren’t sure if you should be concerned? Join CLL Society and Dr. Susan Leclair for this valuable webinar. You will learn how to interpret your blood test results and gain a better understanding of why it is critical to be on top of tracking them in CLL.
Meanwhile, check out these helpful CLL Society lab test links:
During ASH 2020, Steve Bloom, Chair of CLL Society’s Board of Directors, interviewed Dr. Ian Flinn on a next-generation BTK inhibitor zanabrutinib, which is part of a class of drugs that are designed to be more specifically targeted than ibrutinib. The desired outcome is that treatment naïve patients taking zanabrutinib in combination with venetoclax can experience fewer side effects, and hopefully reach uMRD enabling them to discontinue therapy.
This Week’s Featured Articles
Even among CLL patients, the response to the COVID-19 vaccine can vary widely depending on our disease status and which treatments we have had. Dr. Brian Koffman provides a brief refresher, referencing some of our background articles on immunity and directing us to an interesting news article which brings us up-to-date on some of the latest research on this topic. The article goes beyond talking about post-vaccination antibody levels and speculates as to the role T cells might have in protecting us.
Dr. Lindsey Ryan is an emergency room physician, vaccinated but not protected against COVID-19. Her story contrasts the challenges she faces coping with her immunocompromised status with the carefree lives of her friends. A must-read!
Call for Stories on This Topic
If you are facing a similar challenge (vaccinated, but not protected) we welcome you to share your story at firstname.lastname@example.org.
Please Support CLL Society
CLL Society is the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.